

RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Multicomponent Diversity-Oriented Synthesis of Symmetrical and**
2 **Unsymmetrical 1,4-dihydropyridines in Recyclable Glycine Nitrate**
3 **(GlyNO₃) Ionic Liquid: A Mechanistic Insight Using Q-TOF, ESI-**
4 **MS/MS****

5 *Rajesh Kumar,^{a, b} Nitin H. Andhare,^c Amit Shard,^a Richa,^a and Arun Kumar Sinha*^{a, b, c}*
6

7 ^aNatural Plant Products Division, CSIR-Institute of Himalayan Bioresource Technology,
8 Palampur-176061 (H.P.) India

9 ^bAcademy of Scientific and Innovative Research (AcSIR), New Delhi, India

10 ^cMedicinal and Process Chemistry Division, CSIR-Central Drug Research Institute,
11 BS10/1, Sector 10, Janakipuram extension, Sitapur road, Lucknow-226031(U.P), India,

12 E mail*: aksinha08@rediffmail.com

13 ** Some part of work carried our at CSIR-IHBT, Palampur (H.P)

14

15

16

17

18

19

20

21

22

23 **Abstract**

24 Multicomponent reactions are eye-catching strategies to generate chemically diverse set
25 of multifunctionalized heterocyclic motifs with high atom economy manner which render
26 the transformations green. These strategies can further become more prolific if catalyst
27 recyclability, compatibility and exploration of exact mechanistic pathway are taken into
28 account. To this end, an inexpensive and recyclable glycine nitrate (GlyNO₃) ionic liquid
29 has been efficiently employed to access diversely substituted symmetrical and
30 unsymmetrical 1,4-dihydropyridines up to 93% yields via three and four components
31 respectively. The catalyst recyclability and compatibility to access both symmetrical and
32 unsymmetrical 1,4 DHPs under identical reaction conditions, are added benefits to its
33 practical utility. Furthermore, progress of the reaction was monitored by Q-TOF, direct
34 infusion electrospray ionization mass spectrometry (ESI-MS) and key cationic
35 intermediate involved in reaction have been further identified by tandem MS experiment
36 (Q-TOF, ESI-MS/MS) which served as proof-of-concept to the mechanistic model. This
37 is the first report which revealed that the Hantzsch reaction predominately follow
38 diketone path way among four competing reaction pathways.

39

40 **Keywords**

41 1,4-dihydropyridines; ionic liquid; mass spectrometry; multicomponent reaction; reaction
42 mechanism

43

44

45

46 Introduction

47 The creation of multiple carbon-carbon or carbon-hetero bonds in one pot helps in
48 minimization of waste, time and energy. These benefits broadly encompassed under the
49 periphery of green chemistry and generally accomplished by multicomponent reaction
50 (MCRs).¹ In the recent year MCRs have been utilized for the preparation of structurally
51 diverse drug-like compounds;² as a consequence, they have emerged as significant tool in
52 organic synthesis.³

53 One prominent MCR that produces an interesting class of nitrogen based
54 heterocycles is the venerable Hantzsch reaction providing 1,4-dihydropyridines (1,4-
55 DHPs) as privileged pharmacophores.⁴ DHPs derivatives exhibit a wide ranging
56 pharmacological properties.⁵ Initially these molecules recognized as calcium channel
57 modulator but latter on developed as cardiovascular and antihypertensive drugs, which
58 includes, amlodipine, felodipine, nicardipine and nifedipine.⁶ (Figure 1) Beside this, these
59 structural motifs are also credited with versatile biological properties like anticonvulsant,⁷
60 radioprotective,⁸ selective antagonism of adenosine-A3 receptor,⁹ anticancer,¹⁰ HIV
61 protease inhibition,¹¹ and treatment of Alzheimer disease.¹²

62 Conventionally, 1,4-DHPs accessed through Hantzsch reaction, reduction of pyridines,
63 addition to pyridines, or cycloaddition etc.¹³ which suffer from the drawbacks like low
64 to moderate yields besides harsh conditions and longer reaction times. Consequently,
65 several modifications have been developed for the classical Hantzsch approach.¹⁴
66 However, in spite of their potential utility many of these methods still involve expensive
67 and /or toxic catalysts, cumbersome product isolation procedures and incompatibility
68 with certain functional groups, thus are not closer to principles of green chemistry. Hence,

69 the challenge for a sustainable environment calls for more general and viable routes
70 which would be of great relevance to both synthetic and medicinal chemists.

71 In this context, ionic liquids (ILs) hailed as green solvent of the future which increases
72 the portfolio of environmentally benign organic synthesis due to their particular
73 properties such as undetectable vapour pressure, ease of recovery and reuse.¹⁵ So far, ILs
74 with cations derived from imidazolium and guanidinium based ILs have been used as
75 catalysts for Hantzsch reaction.¹⁶ Though these ILs help to reduce the risk of air pollution,
76 concerns are being raised over their potential toxicity to aquatic environments and
77 inaccessible biodegradability.¹⁷

78 Therefore, the development of bio-degradable ILs based on amino acids and their
79 derivatives to replace the above cations is another promising approach because amino
80 acids and their derivatives are the most abundant natural source of quaternary nitrogen
81 precursors.¹⁸ Moreover, low cost, easy preparation, and their properties to act as both
82 anions and cations are added advantage of these amino acid ionic liquids^{18b, e, 19} (AAILs).

83 In continuation of our ongoing endeavours in developing novel and practical
84 multicomponent reactions to synthesized useful heterocyclic compounds,²⁰ we herein
85 present the catalytic efficiency of glycine nitrate (GlyNO₃) ionic liquid under microwave
86 irradiation (MW) for multicomponent synthesis of aromatic/heterocyclic symmetrical and
87 unsymmetrical 1,4-DHPs under identical reaction condition (Scheme 1). Furthermore,
88 detailed Q-TOF, ESI-MS and ESI-MS/MS based mechanistic study revealed that reaction
89 predominately follow diketone path way among four competing pathways.

90

91

92 Results and Discussion

93
94 After an initial survey of reaction conditions, a mixture of 4-chlorobenzaldehyde (**1a**, 0.5
95 mmol), methylacetoacetate (**2a**, 2 equiv), ammonium acetate (**3a**, 2 equiv) and GlyNO₃
96 (0.4 equiv) as a catalyst was irradiated under focused monomode microwave (CEM, P =
97 100 W, 90 °C) for 20 min. in EtOH (0.5 mL) affording 1,4-dihydropyrimidinone **4a** in
98 45% yield (Table 1, entry 1). To further increase the yield of **4a**, different source of
99 ammonium salt were screened (Table 1 entries 2-5) wherein satisfactory yield of **4a** up to
100 73% was obtained with ammonium carbonate (Table 1 entry 5). Thereafter the effect of
101 amount of catalyst (Table 1, entries 6-7) was taken into account and yield of 82 % was
102 obtained with 0.5 equiv. GlyNO₃ (Table 1, entry 6).

103 Further increase in amount of catalyst could not exert any positive influence on
104 the yields of **4a** (Table 1, entry 7). Gratifyingly, the yield was improved to 87% with the
105 increased in volume of EtOH up to 1mL (Table 1, entry 8). Further increase in volume of
106 EtOH fails to enhance the yields of **4a**. Thereafter effects of different solvents and co-
107 solvent (Table 1, entries 9-13), catalysts (Table 1, entries 14-17) were studied, but
108 inferior yields were obtained compared to table 1, entry 8.

109 The control experiments in the absence of solvent and catalyst (Table 1, entries 18-19)
110 afforded **4a** in low yield demonstrated the crucial role of solvent and catalyst. The
111 reaction under conventional condition by refluxing the reaction mixture for 5h fails to
112 improved the yield of **4a** (Table 1, entry 20). Surprisingly, a experiment with glycine
113 (Table 1, entry 21) and HNO₃ (Table 1, entry 22) resulted drastic decrease in yield of **4a**,
114 which emphasized the importance of GlyNO₃ IL in catalysis.

115 With the optimized reaction conditions in hand for synthesis of symmetrical 1,4-DHPs
116 (Table 1, entry 8), the generality and scope of this one pot three component Hantzsch
117 reaction was then explored. For this, a wide range of substituted benzaldehyde including
118 heterocyclic moieties (**1a-i**), methylacetoacetate (**2a**), and ammonium acetate (**3a**) was
119 irradiated under focused MW (P = 100W, 90°C) for 20 min. which produced the
120 corresponding 1,4-DHPs **4a** in good to excellent yields (Table 1, entries **4a-i**). During the
121 substrate scope study, it has been observed that the catalyst exhibited remarkable activity
122 for heterocyclic substituted benzaldehydes particularly for thiophene containing moiety
123 (Table 1, entries **4d-i**). Therefore, we further extended our substrate scope by utilizing
124 different dicarbonyl compound in conjunction with thiophene-2-carboxaldehyde and
125 ammonium carbonate, which afforded the desired compound in good yield (Table 1,
126 entries **4j-l**).

127 After the successful synthesis of three components symmetrical 1,4-DHPs, our
128 goal was to synthesize four component unsymmetrical 1,4-DHPs (also known as
129 polyhydroquinoline) which enjoy the status of being privileged motifs in terms of their
130 diverse biological profiles compared to symmetrical 1,4-DHPs.²¹

131 Recently, these motifs have been recognized as lead molecules in antidiabetic
132 drug discovery.²² There are plethora of reagents and catalyst reported in the literature for
133 the synthesis of unsymmetrical 1,4-DHPs²³ however some of these suffer from
134 limitations like usage of precious class of metal catalyst, longer reaction time (6-11h),
135 two step synthesis, cumbersome product isolation, selectivity and recyclability issues

136 Recently Rajesh et al.^{23x} have also reported hydromagnesite as a heterogeneous solid
137 based catalyst for the synthesis of 1,4-DHPs. Despite promising results, this methodology
138 has limited substrate scope due to non involvement of any heterocyclic benzaldehydes.

139 To the best of our knowledge, there are only few reports available in literature
140 where synthesis of unsymmetrical and symmetrical 1,4-DHPs carried out under identical
141 reaction condition which suffer from drawbacks like longer reaction time, poor substrate
142 scope and tedious synthesis of catalyst.²⁴ Keeping in mind the sheer importance of
143 unsymmetrical 1,4-DHPs, we were also intrigued to investigate whether our developed
144 catalytic system could efficiently result in the synthesis of unsymmetrical 1,4-DHPs by
145 overcoming the existing lacunae of reported protocols.²³

146 Pleasingly, the mixture of 5-bromothiophene-2- carboxaldehyde (**1a**), methyl
147 acetoacetate (**2a**), 5, 5-dimethyl-1, 3-cyclohexanedione (**2b**) and ammonium acetate (**3a**)
148 successfully condensed in one pot under similar reaction condition²⁵ providing **5a** in
149 83 % yield. Thereafter, different substituted aromatic or heterocyclic benzaldehydes (**1a-**
150 **i**) were condensed with **2a**, **2b** and **3a** to afford unsymmetrical 1,4-DHPs (Table 3, **5b-i**)
151 in excellent yields.

152 From an economical point of view, the recyclability of GlyNO₃ was also taken
153 into account. The IL retained high reactivity up to six cycles (Scheme 2).

154 **Mechanistic Study**

155 Mechanistically, it was presumed that there are four plausible pathways²⁶ for the
156 synthesis of symmetrical 1,4-DHPs (Figure 2) These are i) enamine ii) diketone, iii)
157 dienamine and iv) imine pathways (Figure 2 and see the supporting information).

158

159 In order to proven the feasibility of exact pathway among four competing mechanism
160 involved in the synthesis of 1,4- dihydropyridines, preferably used Q-TOF electrospray
161 ionization mass spectrometry (ESI-MS) technique for studying reaction intermediate
162 because of its ability to “fish” ionic or ionized intermediates directly from reaction
163 solutions into the gas phase, with high speed and sensitivity.²⁷ Moreover, its tandem
164 version ESI-MS/MS is rapidly becoming the technique of choice for solution-phase
165 mechanistic studies in chemistry.²⁸

166 Therefore, we performed Q-TOF ESI (+ve) MS studies on aliquots of samples
167 withdrawn after 10 min from GlyNO₃ catalyzed reaction of **1g**, **2a** and **3a** (Scheme 3)²⁹ at
168 capillary voltage (3100 V), cone voltage (25 V), dissolution temp. (200°C) and source
169 temp. (80°C).

170 The total ion chromatogram (TIC) revealed the presence of ions at *m/z* 308.26
171 (*m*₁), 325.29 (*m*₂), 344.31 (*m*₃), 327.31 (*m*₄), 224.15 (*m*₅),³⁰ 211.16(*m*₆), 179.09 (*m*₇), and
172 117.13 (*m*₈) corresponding to [4g + H]⁺, [4g + NH₃ + H]⁺, [11a + H]⁺, [10a + H]⁺, [19a +
173 H]⁺, [7a + H]⁺, [7a – OMe]⁺ and [2a + H]⁺ respectively. The presence of characteristic
174 peaks *m*₃ = [11a + H]⁺, *m*₄ = [10a + H]⁺ and *m*₆ = [7a + H]⁺ in figure 3 revealed the
175 possibility of diketone pathway (Figure 2) and absence of key intermediate **6a** (enamine)
176 **13a** (dienamine) and **17a** (imine) (Scheme 4) in the TIC (Figure 3) ruled out the
177 possibility of enamine, dienamine and imine pathways.

178 For further structure elucidation in context of diketone pathway and product
179 formation, tandem MS/MS experiments were carried out for few selected ions observed
180 in TIC (Figure 3) at *m/z* 308.17 = *m*₁, 325.29 = *m*₂, 344.31 = *m*₃ and 327.31 = *m*₄. The
181 MS/MS or MS² spectra derived from the ion of *m/z* 308.17 = *m*₁ showed peak at *m/z*

182 276.14 and 224.15 assigned as $[4g - OCH_3]^+$ and $[4g - C_4H_3S + H]^+$ (Figure 4),
183 confirmed the product formation.

184 In case of m_2 , the MS^2 spectra (Figure 5) exhibited the parent ion $m_2 = [4g + NH_3$
185 $+ H]^+$ and daughter ion with m/z 308.17, 224.28 corresponded to $[4g - NH_3 + H]^+$ and
186 $[4g - C_4H_3S + H]^+$ respectively, confirmed the ammoniated adduct of desired product i.e.
187 4g (Scheme 3).

188 To further confirm the presence of intermediate (m_3) in context of diketone
189 pathway, the MS^2 experiment was carried out of $m_3 = [11a + H]^+$ ion (Figure 6). The
190 MS/MS spectra revealed the presence of ion with m/z 327.34, 309.31, 295.29 and 211.21
191 which are diagnose as $[11a - NH_2]^+$, $[11a - NH_2 - H_2O]^+$, $[11a - NH_2 - H_2O - CH_3]^+$ and
192 $[11a - NH_2 - H_2O - CH_3 - C_4H_4O_2]^+$ respectively, confirmed the fragments of m_3 and
193 their involvement in diketone pathway.

194 Most importantly, the key intermediate involved in diketone pathway $m_4 = [10a +$
195 $H]^+$ was also ascertain by MS^2 experiment. The MS^2 spectra (Figure 7) exhibited the
196 parent ion $m_4 = [10a + H]^+$ and daughter ions with m/z 295.18, 243.21 and 211.13
197 correspond to $[10a - OCH_3]^+$, $[10a - C_4H_3S]^+$ and $[10a - C_5H_7O_3]^+$ respectively,
198 confirmed the fragments of ion m_4 and their involvement in diketone pathway.

199 On the basis of Q-TOF, ESI -MS/MS studies, it comes to know that GlyNO₃ IL
200 catalyzed three component Hantzsch reaction follows diketone pathway among four
201 competing mechanistic pathways (Figure 2).

202 On the other hand the possibility of enamines pathway cannot be ignored because of
203 observation of peak $m_6 = [7a+H]^+$ (Figure 3) during the analysis of aliquots of samples
204 withdrawn after 10 min, which is also one of the intermediate of enamine pathway

205 (Figure 2). Therefore two control experiments or experiments to validate our perception
206 regarding diketone pathway were carried out in sequential one-pot two step ways
207 (Scheme 5 and 6). The results revealed that 61% of product yield (Scheme 5) was
208 obtained *via* diketone pathway compared to 22% yield *via* enamine pathway (Scheme 6).

209 At last on the basis of control experiments and Q-TOF, ESI-MS/MS study, we
210 can say that the most predominant pathway for the synthesis of symmetrical 1,4-DHPs is
211 diketone rather than enamine, dienamine and imine. This is the first report which proved
212 the participation of diketone pathway in synthesis of symmetrical 1,4-DHPs using Q-TOF,
213 ESI-MS/MS study.

214 **Conclusion**

215
216 In summary, an operationally simple and highly efficient one-pot multicomponent
217 reaction for the synthesis of symmetrical and unsymmetrical 1,4 DHPs have been
218 developed which have sheer importance in synthetic and medicinal chemistry. The
219 methodology is practical, recyclable and economical besides being flexible since it also
220 allows heterocyclic benzaldehydes to participate in synthesis of both symmetrical and
221 unsymmetrical 1,4 DHPs under identical reaction condition. In addition the mechanistic
222 study using Q-TOF, ESI-MS/MS revealed that the synthesis of symmetrical 1,4 DHPs
223 predominate follow diketone pathway among four competing reaction pathways. At last,
224 we anticipate that this catalytic system will find applications in academia and industry.
225 The Q-TOF, ESI-MS/MS based study may also helpful to unveil the mechanistic study of
226 many other reactions. The mechanistic study related to unsymmetrical 1,4 DHPs is
227 currently under investigation.

228

229

230 **Experimental Section**

231

232 **General procedure for the synthesis of symmetrical 1,4-dihydropyridins from**
233 **substituted benzaldehydes (Table 2, 4a-l):** Substituted benzaldehyde (0.5 mmol),
234 dicarbonyl compound (2 equiv.), ammonium carbonate (2 equiv.) and glycine nitrate (0.5
235 equiv.) were taken in 1 mL ethanol in a round bottom flask and the reaction mixture was
236 subjected to microwave irradiation using CEM monomode microwave at P = 100 W,
237 90°C for 20 min. After completion of reaction, the crude reaction mixture
238 was filtered to obtain GlyNO₃. The filtrate was vacuum evaporated and then
239 recrystallization from water–methanol which gave an isolated yield of 4a–l in the range
240 of 52-93 % yields. Products were identified and confirmed by their ¹H, ¹³C NMR spectra
241 and HRMS values.

242 **General procedure for the synthesis of unsymmetrical 1,4-dihydropyridins from**
243 **substituted benzaldehydes (Table 3, 5a-i):** Substituted benzaldehyde (0.5 mmol),
244 methyl acetoacetate (1 equiv.), 5, 5-dimethyl-1, 3-cyclohexanedione (1 equiv.),
245 ammonium carbonate (2 equiv.) and glycine nitrate (0.5 equiv.) were taken in 1 mL
246 ethanol in a round bottom flask and the reaction mixture was subjected to microwave
247 irradiation using CEM monomode microwave at P = 100 W, 90°C for 20 min. After
248 completion of reaction, the crude reaction mixture
249 was filtered to obtain GlyNO₃. The filtrate was vacuum evaporated and then
250 recrystallization from water–methanol which gave an isolated yield of 5a–i in the range
251 of 52-93 % yields. Products were identified and confirmed by their ¹H, ¹³C NMR spectra
252 and HRMS values.

253

254 **Acknowledgements**

255

256 RK, NHA and AS are indebted to CSIR, New Delhi, for the award of research
257 fellowships. The authors gratefully acknowledge Director, IHBT, Palampur and Director,
258 CDRI, Lucknow for their kind cooperation and encouragement. This work was supported
259 by Council of Scientific and Industrial Research (project CSC-0108 and ORIGIN).
260 Thanks to Mr. Shiv Kumar and Pawan Kumar for providing spectral data.

261 **Electronic Supplementary Information (ESI) available:**262 ¹H and ¹³C NMR data and spectra of symmetrical and unsymmetrical 1,4-DHPs

263

264 **References**

265

- 266 1 (a) B. B. Toure and D. G. Hall, *Chem. Rev.*, 2009, **109**, 4439–4486; (b) J. D.
267 Sunderhaus and S. F. Martin, *Chem. Eur. J.*, 2009, **15**, 1300–1308; (c) B. Ganem,
268 *Acc. Chem. Res.*, 2009, **42**, 463–472; (d) N. Ismabery and R. Lavila, *Chem.–Eur.*
269 *J.*, 2008, **14**, 8444–8454; (e) D. M. D. Souza and T. J. J. Mueller, *Chem. Soc. Rev.*,
270 2007, **36**, 1095–1108; (f) B. Jang, F. Shi and S.-T. Tu, *Curr. Org. Chem.*, 2010,
271 **14**, 357–378; (g) B. Jiang, T. Rajale, W. Wever, S.-J. Tu and G. Li, *Chem. Asian*
272 *J.*, 2010, **5**, 2318–2335; (h) A. Domling, *Chem. Rev.*, 2006, **106**, 17-89; (i) J.
273 Zhu, *Eur. J. Org. Chem.*, 2003, 1133-1144; (j) D. J. Ramon and M. Yus, *Angew.*
274 *Chem., Int. Ed.*, 2005, **44**, 1602-1634; (k) N. Isambert and R. Lavilla, *Chem. Eur.*
275 *J.*, 2008, **14**, 8444 – 8454; (l) Y. Gu, *Green Chem.*, 2012, **14**, 2091-2128.
- 276 2 (a) Ugi, A. Domling and W. Horl, *Endeavour*, 1994, **18**, 115–122; (b) L. F. Tietze
277 and A. Modi, *Med. Res. Rev.*, 2000, **20**, 304–322; (c) R. V. A. Orru and M. D.
278 Greef, *Synthesis*, **2003**, 1471–1499.
- 279 3 (a) A. Pinto, L. Neuville and J. Zhu, *Angew. Chem. Int. Ed.*, 2007, **46**, 3291-3295;
280 (b) M. R. M. Huettl, *Angew. Chem. Int. Ed.*, 2007, **46**, 1570-1581; (c) L. F. Tietze,
281 N. Rackelmann, *Pure Appl. Chem.*, 2004, **76**, 1967-1983; (d) L. F. Tietze, *Chem.*

- 282 *Rev.*, 1996, **96**, 115-136; (e) P. Arya, R. Joseph and D. T. H. Chou, *Chem. Biol.*,
283 2002, **9**, 145-156.
- 284 4 J.-P. Wan and Y. Liu, *RSC Advances*, 2012, **2**, 9763–9777.
- 285 5 (a) A. Hilgeroth and H. Lilie, *Eur. J. Med. Chem.*, 2003, **38**, 495-499; (b) C.
286 Avendano and J. C. Menendez, *Curr. Med. Chem.*, 2002, **9**, 159-193; (c) C.
287 Avendano and J. C. Menendez, *Med. Chem. Rev.*, 2004, **1**, 419-444; (d) A.
288 Boumendjel, H. B. Cortay, D. Trompier, T. Perrotton and A. D. Pietro, *Med. Res.*
289 *Rev.*, 2005, **25**, 453-472; (e) I. O. Donkor, X. Zhou, J. Schmidt, K. C. Agrawal
290 and V. Kishore, *Bioorg. Med. Chem.*, 1998, **6**, 563-566; (f) K. S. Atwal, B. N.
291 Swanson, S. E. Unger, D. M. Floyd, S. Mereland, A. Hedberg and B. C. O'Reilly,
292 *J. Med. Chem.*, 1991, **34**, 806-811.
- 293 6 (a) G. C. Rovnyak, S. D. Kimball, B. Beyer, G. Cucinotta, J. D. Dimarco, J.
294 Gougoutas, A. Hedberg, M. Malley, J. P. MaCarthy, R. Zhang and S. Mereland, *J.*
295 *Med. Chem.*, 1995, **38**, 119-129; (b) C. O. Kappe, W. M. F. Fabian and M. A.
296 Semones, *Tetrahedron*, 1997, **53**, 2803-2816; (c) K. Aouam, A. Berdeaux,
297 *Therapiem*, 2003, **58**, 333-339; (d) A. Hilgeroth, *Mini-Rev. Med. Chem.* 2002, **2**,
298 235-247.
- 299 7 K. K. Borowicz, M. Gasior, Z. Kleinrok and S. J. Czuczwar, *Eur. J. Pharmacol.*,
300 1997, **323**, 45–51.
- 301 8 I. O. Donkor, X. Zhou, J. Schmidt, K. C. Agrawal and V. Kishore, *Bioorg. Med.*
302 *Chem.*, 1998, **6**, 563–568.
- 303 9 H. Li, S. Moro, N. Forsyth, N. Melman, X.-D. Ji and K. A. Jacobson, *J. Med.*
304 *Chem.*, 1999, **42**, 706–721.
- 305 10 (a) S. R. M. D. Morshed, K. Hashimoto, Y. Murotani, M. Kawase, A. Shah,
306 K. Satoh, H. Kikuchi, H. Nishikawa, J. Maki and H. Sakagami, *Anticancer Res.*,
307 2005, **25**, 2033-2038; (b) H. A. S. Abbas, W. A. El Sayed and N. M. Fathy, *Eur.*
308 *J. Med. Chem.*, 2010, **45**, 973-982; (c) X. Zhou, L. Zhang, E. Tseng, E. Scott-
309 Ramsay, J. J. Schentag, R. A. Coburn and M. E. Morris, *Drug Metab. Dispos.*,
310 2005, **33**, 321-328; (d) L. Bazargan, S. Fouladdel, A. Shafiee, M. Amini, S. M.
311 Ghaffari and E. Azizi, *Cell Biol. Toxicol.*, 2008, **24**, 165-174.

- 312 11 (a) A. Hilgeroth, *Mini-Rev. Med. Chem.*, 2002, **2**, 235; (b) A. Hilgeroth and H.
313 Lilie, *Eur. J. Med. Chem.*, 2003, **38**, 495-503; (c) A. Hilgeroth, M. Wiese and A.
314 Billich, *J. Med. Chem.*, 1999, **42**, 4729-4732.
- 315 12 J. Marco-Counntelles, R. Leon, C. de los Rios, A. Guglietta, J. Terencio, M .G.
316 Lopez, A. G. Garcia and M. Villarroya, *J. Med. Chem.*, 2006, **49**, 7607-7610.
- 317 13 (a) U. Eisner and J. Kuthan, *Chem. Rev.*, 1972, **72**, 1-42; (b) D. M. Stout and A.
318 I. Meyers, *Chem. Rev.*, 1982, **82**, 223-243; (c) A. Sausins and G. Duburs,
319 *Heterocycles*, 1988, **27**, 269-289.
- 320 14 (a) N. Koukabi, E. Kolvari, A. Khazaei, M. A. Zolfigol, B. S. Shaghasemi and
321 H. R. Khavasi, *Chem. Commun.*, 2011, **47**, 9230-9232; (b) R. Ananthakrishnan
322 and S. Gazi, *Catal. Sci. Technol.*, 2012, **2**, 1463-1471; (c) L. Shen, S. Cao, J. Wu,
323 J Zhang, H. Li, N. Liu and X. Qian, *Green Chem.*, 2009, **11**, 1414-1420; (d) M.
324 M.-Aghayan, R. Boukherroub, M. Nemati and M. Rahimifard, *Tetrahedron Lett.*,
325 2012, **53**, 2473-2475; (e) A. Debache, R. Boulcina, A. Belfaitah, S. Rhouti and B.
326 Carboni, *Synlett*, 2008, 509-512; (f) S. Thakrar, A. Bavishi, D. Bhavsar, S. Parekh,
327 H. Vala, A. Radadiya, M. Parmar and M. Savant, *Synth. Commun.*, 2012, **42**,
328 3269-3278; (g) S. Rostamnia and K. lamei, *Chin. Chem. Lett.*, 2012, **23**, 930-932;
329 (h) A. Kuraitheerthakumaran, S. Pazhamalai and M. Gopalakrishnan, *Chin. Chem.*
330 *Lett.*, 2011, **22**, 1199-1202; (i) A. Debache, W. Ghalem, R. Boulcina, A. Belfaitah,
331 S. Rhouati and B. Carboni, *Tetrahedron Lett.*, 2009, **50**, 5248-5250; (j) F.
332 Tamaddon, Z. Razmi and A. A. Jafari, *Tetrahedron Lett.*, 2010, **51**, 1187-1189;
333 (k) R. S. Varma and D. Kumar, *Tetrahedron Lett.*, 1999, **40**, 21-24; (l) H. Salehi
334 and Q.-X. Guo, *Synth. Commun.*, 2004, **34**, 4349-4357; (m) M. Kidwai, S. Saxena,
335 R. Mohan and R. Venkataramanan, *J. Chem. Soc., Perkin Trans. 1*, 2002, 1845-
336 1846; (n) G. Sabitha, G. S. K. K. Reddy, C. S. Reddy and J. S. Yadav,
337 *Tetrahedron Lett.*, 2003, **44**, 4129-4131; (o) A. Dondoni, A. Massi, E.
338 Minghini and V. Bertolasi, *Tetrahedron Lett.*, 2004, **60**, 2311-2326; (p) R. K.
339 Vohra, C. Bruneau and J.-L. Renaud, *Adv. Synth. Catal.*, 2006, **348**, 2571-2574;
340 (q) N. Koukabi, E. Kolvari, M. A. Zolfigol, A. Khazaei, B. S. Shaghasemi and B.
341 Fasahati, *Adv. Synth. Catal.*, 2012, **354**, 2001-2008

- 342 15 (a) R. D. Rogers and K. R. Seddon, *Science*, 2003, **302**, 792–793; (b) J. P. Hallett
343 and T. Welton, *Chem. Rev.*, 2011, **111**, 3508–3576; (c) P. Hapiot and C.
344 Lagrost, *Chem. Rev.*, 2008, **108**, 2238–2264; (d) T. L. Greaves and C. J.
345 Drummond, *Chem. Rev.*, 2008, **108**, 206–237; (e) J. Dupont, R. F. de Souza
346 and P. A. Z. Suarez, *Chem. Rev.*, 2002, **102**, 3667–3692.
- 347 16 (a) J.-C. Legeay, J. J. V. Eynde and J. P. Bazureau, *Tetrahedron*, 2005, **61**, 12386-
348 12397; (b) L. Ming, G. W.-Si, W. L.-Rong, L. Y.- Feng and Y. H.- Zheng, *J.*
349 *Mol. Catal. A: Chem.*, 2006, **258**, 133-138; (c) A. Shaabani, A. H. Rezayan and
350 A. Rahmati, *Monatshefte für Chemie/Chemical Monthly*, 2006, **137**, 77-81; (d) J.
351 S. Yadav, B. V. S. Reddy, A. K. Basak and A.V. Narsaish, *Green Chem.*, 2003,
352 **5**, 60-63.
- 353 17 (a) K. S. Egorova and V. P. Ananikov, *ChemSusChem*, 2014, **7**, 336-360; (b) R. P.
354 Swatloski, J. D. Holbrey and Robin D. Rogers, *Green Chem.*, 2003, **5**, 361-363;
355 (c) N. Gathergood, M. T. Garcia, and P. J. Scammells, *Green Chem.*, 2004, **6**,
356 166-176; (d) G.-H. Tao, L. He, W.-S. Liu, L. Xu, W. Xiong, T. Wang and Yuan
357 Kou, *Green Chem.*, 2006, **8**, 639-646.
- 358 18 (a) W. Bao, Z. Wang and Y. Li, *J. Org. Chem.*, 2003, **68**, 591–593; (b) K.
359 Fukumoto and H. Ohno, *Chem. Commun.*, 2006, 3081–3083; (b) K. Fukumoto, M.
360 Yoshizawa and H. Ohno, *J. Am. Chem. Soc.*, 2005, **127**, 2398–2399; (c) L. C.
361 Branco, P. M. P. Gois, N. M. T. Lourenco, V. B. Kurteva and C. A. M. Afonso,
362 *Chem. Commun.*, 2006, 2371–2372; (d) G. H. Tao, L. He, N. Sun and Y. Kou,
363 *Chem. Commun.*, 2005, 3562–3564; (e) G. H. Tao, L. He, W. S. Liu, L. Xu, W.
364 Xiong, T. Wang and Y. Kou, *Green Chem.*, 2006, **8**, 639–646.
- 365 19 (a) H. Ohno and K. Fukumoto, *Acc. Chem. Res.*, 2007, **40**, 1122–1129.
- 366 20 (a) R. Kumar, Richa, N. H. Andhare, A. Shard and A. K. Sinha, *Chem. Eur. J.*
367 2013, **19**, 14798 – 14803; (b) N. Sharma, U. K. Sharma, R. Kumar, Richa and A.
368 K. Sinha, *RSC Advances*, 2012, **2**, 10648–10651; (c) U. K. Sharma, N. Sharma, R.
369 Kumar and A. K. Sinha, *Amino Acids*, 2013, **44**, 1031–1037.
- 370 21 One of the main advantage of unsymmetrical 1,4-DHPs is utilization of two
371 different dicarbonyl compounds which result increased in diversified
372 derivative of 1,4 DHPs compared to symmetrical 1,4-DHPs where two similar

- 373 dicarbonyl are utilized. Overall the possibility of discovering new biological
374 entities increased.
- 375 22 (a) A. Kumar, S. Sharma, V. D. Tripathi, R. A. Maurya, S. P. Srivastava, G.
376 Bhatia, A. K. Tamrakar and A. K. Srivastava, *Bioorg. Med. Chem.*, 2010, **18**,
377 4138-4148; (b) L. E. Hinkel, *J. Chem. Soc. Trans.*, 1920, **117**, 137-140.
- 378 23 (a) L. Saikia, D. Dutta and D. K. Dutta, *Catal. Commun.*, 2012, **19**, 1-4; (b) L.- M.
379 Wang, J. Sheng, L. Zang, J.-W. Han, Z.-Y. Fan, H. Tian and C.-T. Qian,
380 *Tetrahedron*, 2005, **61**, 1539-1543; (c) S. K. Kumar and K. N. Singh, *J.*
381 *Heterocycl. Chem.*, 2010, **47**, 194-197; (d) M. Maheswara, V. Siddaiah, G. L. V.
382 Damu and C. V. Rao, *ARKIVOC*, 2006, ii, 201-206; (e) M. Kidwai, R. Chauhan,
383 D. Bhatnagar, A. K. Singh, B. Mishra and S. Dey, *Montash Chem.*, 2012, **143**,
384 1675-1680; (f) D. S. Raghuvanshi and K. N. Singh, *Indian J. Chem.*, 2013, **52B**,
385 1218-1223; (g) K. A. Undale, T. S. Shaikh, D. S. Gaikwad and D. M. Pore, *C. R.*
386 *Chimie.*, 2011, **14**, 511-515; (h) J. P. Nirmal, P. V. Dadhaniya, M. P. Patel and R.
387 G. Patel, *Indian J. Chem.*, 2010, **49B**, 587-592; (i) A. Rajendran, C. Karthikeyan
388 and K. Rajathi, *Int. J. Chem Tech. Res.*, 2011, **3**, 810-816; (j) E. Rajanarendar, M.
389 N. Reddy and S. Raju, *Indian J. Chem. Sect B*, 2011, **50**, 751-755; (k) W. H.
390 Correa and J. L. Scott, *Green Chem.*, 2001, **3**, 296-301; (l) J. L. Donelson, R. A.
391 Gibas and S. K. De, *J. Mol. Catal. A:Chem.*, 2006, **256**, 309-311; (m) A. Kumar
392 and R. A. Maurya, *Tetrahedron Lett.*, 2007, **48**, 3887-3890; (n) S. Ko and C.-F.
393 Yao, *Tetrahedron*, 2006, **62**, 7293-7299; (o) M. M. Heravi, K. Bakhtiari, N. M.
394 Javadi, F. F. Bamoharram, M. SEADI and H. A. Oskooie, *J. Mol. Catal. A:*
395 *Chem.*, 2007, **264**, 50-52; (p) J. C. Legeay, J. Y. Goujon, J. J. V. Eynde, L.
396 Toupet and J. P. Bazureau, *J. Comb. Chem.*, 2006, **8**, 829-833; (q) S. Ko, M. N.
397 V. Sastry, C. Lin and C.-F. Yao, *Tetrahedron Lett.*, 2005, **46**, 5771-5774; (r) M.
398 Tajbakhsh, H. Alinezhad, M. Norouzi, S. Baghery and M. Akbari, *J. Mol. Liq.*,
399 2013, **177**, 44-48; (s) A. Kumar and R. A. Maurya, *Tetrahedron*, 2007, **63**,
400 1946-1952; (t) N. N. Karade, V. H. Budhewar, S. V. Shinde and W. N. Jadhav,
401 *Lett. Org. Chem.*, 2007, **4**, 16-19; (u) G. Song and B. Wang, *Synth. Commun.*,
402 2005, **35**, 2875-2878; (v) S. R. Cherkupally and R. Mekala, *Chem. Pharm. Bull.*,
403 2008, **56**, 1002-1004; (w) X.-L. Zhang, S.-R. Sheng, X.-L. Lu and X.-L. Liu,

- 404 *ARKIVOC*, 2007, xiii, 79-86; (x) U. C. Rajesh, S. Manohar and D. S. Rawat *Adv.*
405 *Synth. Catal.*, 2013, **355**, 3170-3178; (y) M. M. Heravi, M. Saeedi, N. Karimi, M.
406 Zakeri, Y. S. Beheshtiha, A. Davoodnia, *Synth. Commun.*, 2010, **40**, 523–529,
407 24 (a) R. F. Affeldf, E. V. Benveutti and D. Russowsky, *New J. Chem.*, 2012, **36**,
408 1502-15011; (b) M. N. Esfahani, S. J. Hoseini, M. Montazerzohori and R.
409 Mehrabi, H. Nasrabadi, *J. Mol. Catal A: Chem.*, 2014, **382**, 99-105; (c) P. P.
410 Ghosh, S. Paul and A. R. Das, *Tetrahedron Lett.*, 2013, **54**, 138-142.
- 411 25 The synthesis of four component unsymmetrical 1,4 DHPs carried out under
412 similar reaction condition as adopted for three components synthesis of
413 symmetrical 1,4 DHPs (Table 1, entry 8). The difference is only in the
414 utilization of methylacetoacetate and dimedone (1:1 equiv) instead of 2 equiv
415 of methylacetoacetate.
- 416 26 (a) A. R. Katritzky, D. L. Ostercamp and T. I. Yousaf, *Tetrahedron*, 1986, **42**,
417 5729- 5738; (b) A. Saini, S. Kumar and J. S. Sandhu, *J. Sci. Ind. Res.*, 2008, **67**,
418 95-111; (c) A.R. Katritzky, D. L. Ostercamp and T. I. Yousaf, *Tetrahedron*, 1987,
419 **43**, 5171-5186; (d) J. A. Berson and E. Brown, *J. Am. Chem. Soc.*, 1955, **77**, 444-
420 447; (e) B. Singh and G. Y. Leshner, *J. Heterocycl. Chem.*, 1980, **17**, 1109-1110;
421 (f) P. A. Hopes, A. J. Parker and I. Patel, *Org. Process Res. Dev.*, 2006, **10**,
422 808–813.
- 423 27 (a) J. B. Fenn, M. Mann, C. K. Meng, S. F. Wong and C. M. Whitehouse,
424 *Science*, 1989, **246**, 64-71; (b) D. Schroder, *Acc. Chem. Res.*, 2012, **45**, 1521-
425 1532; (c) L. S. Santos, *Eur. J. Org. Chem.*, 2008, 235–253; (d) M. Schafer,
426 M. Drayß, A. Springer, P. Zacharias and K. Meerholz, *Eur. J. Org. Chem.*, 2007,
427 5162–5174; (e) J. B. Fenn, Electrospray Wings for Molecular Elephants (Nobel
428 Lecture). *Angew. Chem. Int. Ed.*, 2003, **42**, 3871–3894; (f) R. B. Cole, *J. Mass.*
429 *Spectrom.*, 2000, **35**, 763–772.
- 430 28 C. Silvestri and J. S. Brodbelt, *Mass Spectrometry Reviews*, 2013, **32**, 247–266.
- 431 29 Thiophene-2-carboxaldehyde was taken as model substrate for mechanistic
432 study because of following region i) gave maximum yield of product, ii) their
433 better solubility in EtOH and iii) ease in Q-TOF, ESI-MS analysis.

434 30 The peak $[19a + H]^+ = m_5$ corresponds to fragmented part of peak 4g i.e. $[4g-$
 435 $C_4H_3S]^+$ which is further stabilized to 3,5-dimethyl 2,6-dimethylpyridine-3,5-
 436 dicarboxylate $[19a + H]^+$ (see supporting information).

437

438


439

440

441

442

443

444 **Graphical Abstract****Key points:-**

- i) First report proved the involvement of diketone pathway in 1,4 DHPs synthesis.
- ii) Characterization of intermediates using Q-TOF, ESI-MS/MS.
- iii) Catalyst compatibility to both symmetrical and unsymmetrical 1,4 DHPs under identical reaction condition.

445

446

447 Glycine nitrate ionic liquid (GlyNO₃) has been explored for the synthesis of symmetrical and
 448 unsymmetrical 1,4-DHPs in good to excellent yield under identical reaction condition. Moreover,
 449 Q-TOF, ESI-MS/MS based mechanistic study revealed the diketone as predominate pathway for
 450 the synthesis of symmetrical 1,4-DHPs.

451

452

453


454

455

456

457

458

Table 1. Optimization study for the synthesis of 1,4-dihydropyridins ^a

S. No.	Ammonium salt	Solvent	Ionic Liquid	Yield ^[b] (%)
1	NH ₄ OAc	EtOH	GlyNO ₃	45
2	NH ₄ BF ₄	EtOH	GlyNO ₃	30
3	NH ₄ Cl	EtOH	GlyNO ₃	20
4	NH ₄ HCO ₃	EtOH	GlyNO ₃	70
5	(NH ₄) ₂ CO ₃	EtOH	GlyNO ₃	73
6 ^c	(NH ₄) ₂ CO ₃	EtOH	GlyNO ₃	82
7 ^d	(NH ₄) ₂ CO ₃	EtOH	GlyNO ₃	80
8^e	(NH₄)₂CO₃	EtOH	GlyNO₃	87
9	(NH ₄) ₂ CO ₃	H ₂ O	GlyNO ₃	19
10	(NH ₄) ₂ CO ₃	DCM	GlyNO ₃	34
11	(NH ₄) ₂ CO ₃	DMSO	GlyNO ₃	20
12	(NH ₄) ₂ CO ₃	PEG 400	GlyNO ₃	30
13	(NH ₄) ₂ CO ₃	EtOH:H ₂ O	GlyNO ₃	40
14	(NH ₄) ₂ CO ₃	EtOH	GlySO ₄	66
15	(NH ₄) ₂ CO ₃	EtOH	GlyTFA	40
16	(NH ₄) ₂ CO ₃	EtOH	GlyOAc	59
17	(NH ₄) ₂ CO ₃	EtOH	GlyCl	57
18	(NH ₄) ₂ CO ₃	-	GlyNO ₃	29
19	(NH ₄) ₂ CO ₃	EtOH	-	26
20 ^f	(NH ₄) ₂ CO ₃	EtOH	GlyNO ₃	55
21	(NH ₄) ₂ CO ₃	EtOH	Glycine	65
22	(NH ₄) ₂ CO ₃	EtOH	HNO ₃	20


459

460 ^a Experimental conditions: 0.5 mmol of 4-chlorobenzaldehyde, methylacetoacetate (2
 461 equiv), (NH₄)₂CO₃ (2 equiv), GlyNO₃ (0.5 equiv) in 1 mL of EtOH under MW at P = 100
 462 W, 90°C for 20 min, ^b Isolated yield (after recrystallization in water and methanol).
 463 ^c GlyNO₃ (0.5 equiv), ^d GlyNO₃ (0.6 equiv) ^e EtOH (1mL), ^f reflux for 5h. For entries 1-7
 464 EtOH = 0.5 mL, entries 8-22 solvent = 1 mL.
 465

466

467

468 **Table 2.** Substrate scope of *GlyNO*₃ catalyzed synthesis of symmetrical 1,4-
 469 dihydropyridines ^a



470


471

472 ^a Experimental conditions: 0.5 mmol of substituted benzaldehyde, methylacetoacetate (2
 473 equiv), (NH₄)₂CO₃ (2 equiv), *GlyNO*₃ (0.5 equiv) in 1 mL of EtOH under MW at P = 100
 474 W, 90°C for 20 min, ^b Isolated yield (after recrystallization in water & methanol).
 475

476

477

478 **Table 3.** Substrate scope of *GlyNO*₃ catalyzed synthesis of unsymmetrical 1,4-
 479 dihydropyridines ^a



480

481 ^a Experimental conditions: 0.5 mmol of substituted benzaldehyde, **2a** (1 equiv), **3a** (1

482 equiv), (NH₄)₂CO₃ (2 equiv), *GlyNO*₃ (0.5 equiv) in 1 mL of EtOH under MW at P = 100

483 W, 90°C, for 20 min. ^b Isolated yield (after recrystallization in water & methanol).

484

485


486

487

488


489

490
491



492
493
494
495
496
497


Scheme 1. Synthesis of symmetrical and unsymmetrical 1,4-dihydropyridines in GlyNO₃ ionic liquid via three and four component reaction.



498


Scheme 2. Recyclability study of catalyst for the synthesis of 1,4-dihydropyridines

500



501
502
503


Scheme 3. The one-pot three component Hantzsch reaction



505 **Scheme 4.** Key intermediates of four plausible pathways

506

507




508

509

Scheme 5. Sequential one-pot two step synthesis of 1,4-DHP via diketone pathway.

510



511

512

513

514

515

516

517

518

519

520

Scheme 6. Sequential one-pot two step synthesis of 1,4-DHP via enamine pathway.




Figure 1. 1, 4 DHPs used as clinical drugs.

521
522
523
524
525
526
527
528
529




530
531

Figure 2. Different plausible pathways for the synthesis of 1, 4-dihydropyridines.



532

533 **Figure 3.** TIC of Q-TOF, ESI (+) MS of sample withdrawn after 10 min for three-component
534 Hantzsch reaction of **1g**, **2a** and **3a** catalyzed by GlyNO₃.




535

536

537


Figure 4. On line Q-TOF, ESI (+) MS/MS of peak $m_1 = 308.17$ as shown in figure 2.



538

539

Figure 5. On line Q-TOF, ESI (+) MS/MS of peak $m_2 = 325.29$ as shown in figure 2.




540

541

542

Figure 6. On line Q-TOF, ESI (+) MS/MS of peak $m_3 = 344.31$ as shown in figure 2.



543

544

545

Figure 7. On line Q-TOF, ESI (+) MS/MS of peak $m_4 = 327.31$ as shown in figure 2.